No Pozdnyakov
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
No Pozdnyakov has a total of 27 co-authors. Here are the top co-authors by number of shared publications:
- Alexei E. Miroshnikov
LLC ClinPharmInvest
2 shared publications - A. A. Khokhlov
LLC "AX CT
1 shared publication - A. A. Milkina
Clinical Hospital “RZhD-Meditsina” of Yaroslavl
1 shared publication - A. M. Sirotkina
Yaroslavl State Medical University, Yaroslavl, Russian Federation
1 shared publication Ae Miroshnikov
Yaroslavl State Medical University, Yaroslavl, Russia
1 shared publication- Aleksandr Leonidovich Khokhlov
Yaroslavl State Medical University
1 shared publication
Latest Publications
- 5 May 2025
- Published by Bionika Media in Urologiia
- Vol. 2_2025
Results of the use of the drug Superlymph® in the treatment of chronic cystitis according to clinical studies
- 5 May 2025
- Published by Bionika Media in Urologiia
- Vol. 2_2025
Results of the use of the drug Superlymph® in the treatment of chronic cystitis according to clinical studies
- Open Access
- 3 July 2023
- Published by Paediatrician Publishers LLC in Annals of the Russian academy of medical sciences
- Vol. 78 (3) , 194-207
Socio-Psychological Aspects of Introducing Mobile Technologies into Clinical Trials
Background: High political and economic turbulence, changes in the international relations and cross-national economic ties enhance the demand for developing and launching new pharmacological treatments as a part of nationally independent health care program and import substitution policy. The number of clinical trials is growing rapidly, increasing the need for more effective solutions in organizing these trials optimizing the time, financial resources and efforts of medical personnel. The global trend of creating a new digital ecosystem in health care also raises the issues of higher patient involvement, taking into account the patient's psychological and physical barriers including the issues of personal data security. Aims: Evaluating the motivation and readiness of current clinical trials participants to switch to mobile technologies and identifying the barriers for these shifts. Method: The survey among 75 participants of clinical trials using offline self-completed questionnaire, data processing using statistical tools for data analysis. Results: Currently, 56% of respondents who are current participants of traditional medical trials would definitely agree to participate in mobile clinical trials. Compared to the consistency rate between traditional clinical trials estimated as 73%, the shift to a new format will result in 17% additional losses. The serious barrier for participation is the concerns about the security of personal information it is highly relevant for 37% of respondents and moderately relevant for 44%. The important motivating factor for the participation is the open access to personal medical data - 44% of respondents were highly interested in obtaining this data and 31% are somewhat interested. Conclusion. The results of the pilot study confirmed relatively high readiness of current participants to join mobile clinical trials and use mobile devices and solutions in future trials. However the level of readiness is unequal between different socio-demographic groups. Differentiating parameters are age, former experience of clinical trials and the skills in using digital technologies. Training programs for managers and researchers of clinical trials, provision of devices for non-users, timely technical support during the data collection and transparency in data usages can help to address key issues which slow down the peoples participation in mobile trials.
- 3 July 2023
- Published by Paediatrician Publishers LLC in Annals of the Russian academy of medical sciences
- Vol. 78 (3) , 194-207
Open AccessSocio-Psychological Aspects of Introducing Mobile Technologies into Clinical Trials
Background: High political and economic turbulence, changes in the international relations and cross-national economic ties enhance the demand for developing and launching new pharmacological treatments as a part of nationally independent health care program and import substitution policy. The number of clinical trials is growing rapidly, increasing the need for more effective solutions in organizing these trials optimizing the time, financial resources and efforts of medical personnel. The global trend of creating a new digital ecosystem in health care also raises the issues of higher patient involvement, taking into account the patient's psychological and physical barriers including the issues of personal data security. Aims: Evaluating the motivation and readiness of current clinical trials participants to switch to mobile technologies and identifying the barriers for these shifts. Method: The survey among 75 participants of clinical trials using offline self-completed questionnaire, data processing using statistical tools for data analysis. Results: Currently, 56% of respondents who are current participants of traditional medical trials would definitely agree to participate in mobile clinical trials. Compared to the consistency rate between traditional clinical trials estimated as 73%, the shift to a new format will result in 17% additional losses. The serious barrier for participation is the concerns about the security of personal information it is highly relevant for 37% of respondents and moderately relevant for 44%. The important motivating factor for the participation is the open access to personal medical data - 44% of respondents were highly interested in obtaining this data and 31% are somewhat interested. Conclusion. The results of the pilot study confirmed relatively high readiness of current participants to join mobile clinical trials and use mobile devices and solutions in future trials. However the level of readiness is unequal between different socio-demographic groups. Differentiating parameters are age, former experience of clinical trials and the skills in using digital technologies. Training programs for managers and researchers of clinical trials, provision of devices for non-users, timely technical support during the data collection and transparency in data usages can help to address key issues which slow down the peoples participation in mobile trials.
- 25 February 2023
- Published by Pirogov Russian National Research Medical University
- No. 2023(1)
The trouble with antibiotics
During the long history of antibiotics, resistance of causative agents of main infectious diseases was estimated as a very serious threat to effective treatment of patients and as a social and economic problem faced by the entire mankind. The activities performed by the medical society provided no significant effect resulting in growing antibiotic resistance. The pandemic of novel coronavirus infection only made things worse. It became a new challenge for the medical community regarding searching solutions which are clinical, organizational and methodological by nature in the global struggle with resistance to antibiotics. The reviews of several studies of coronaviral infections have shown that treatment with antibiotics failed to correlate with the decreased all-cause mortality. In this work, we have reviewed some aspects of therapy with antibiotics, including ethical ones. Ethical aspects of antibiotic therapy concern decisions of physicians about administration of commonly unnecessary antimicrobial agents.
- 25 February 2023
- Published by Pirogov Russian National Research Medical University
- No. 2023(1)
The trouble with antibiotics
During the long history of antibiotics, resistance of causative agents of main infectious diseases was estimated as a very serious threat to effective treatment of patients and as a social and economic problem faced by the entire mankind. The activities performed by the medical society provided no significant effect resulting in growing antibiotic resistance. The pandemic of novel coronavirus infection only made things worse. It became a new challenge for the medical community regarding searching solutions which are clinical, organizational and methodological by nature in the global struggle with resistance to antibiotics. The reviews of several studies of coronaviral infections have shown that treatment with antibiotics failed to correlate with the decreased all-cause mortality. In this work, we have reviewed some aspects of therapy with antibiotics, including ethical ones. Ethical aspects of antibiotic therapy concern decisions of physicians about administration of commonly unnecessary antimicrobial agents.
- 27 May 2022
- Published by Pirogov Russian National Research Medical University
- No. 2022(1)
Review of ‘Ethical examination in biomedical research: practical considerations’ for ethics committees (third edition, revised and enlarged) under the general editorship of Khokhlov AL
The article reviews the edition known as ‘Ethical Examination in Biomedical Research: Practical Considerations’ (third edition, revised and enlarged) under the general editorship of Professor Khokhlov AL, a corresponding member of the Russian Academy of Sciences. Due to a constantly growing number of clinical trials of medicinal products and improved level and quality of medical technologies, the role of an ethical examination aimed at compliance with ethical rights of trial participants and consumers, and safety aspects is increased. The article sums up what was described in the published edition.
- 27 May 2022
- Published by Pirogov Russian National Research Medical University
- No. 2022(1)
Review of ‘Ethical examination in biomedical research: practical considerations’ for ethics committees (third edition, revised and enlarged) under the general editorship of Khokhlov AL
The article reviews the edition known as ‘Ethical Examination in Biomedical Research: Practical Considerations’ (third edition, revised and enlarged) under the general editorship of Professor Khokhlov AL, a corresponding member of the Russian Academy of Sciences. Due to a constantly growing number of clinical trials of medicinal products and improved level and quality of medical technologies, the role of an ethical examination aimed at compliance with ethical rights of trial participants and consumers, and safety aspects is increased. The article sums up what was described in the published edition.
- Open Access
- 13 July 2020
- Published by FSPSI SCFHHRP in Acta Biomedica Scientifica
- Vol. 5 (3) , 13-23
Pharmacogenetic Aspects of Type 2 Diabetes Treatment
In this article, we analyze the role of different variants of the KCNJ11, TCF7L2, SLC22A1, SLC22A3, CYP2C9, CYP2C8, PPARγ genes polymorphisms in efficacy of diabetes mellitus pharmacotherapy. T allele of the KCNJ11 rs2285676 gene polymorphism and G allele of KCNJ11 rs5218 gene polymorphism are associated with the response to IDPP-4 therapy; the presence of KCNJ11 gene rs5210 polymorphism A allele is a predictor of poor response. The effect of rs7903146 polymorphism of TCF7L2 gene was evaluated on the response to treatment of patients taking linagliptin. Linagliptin significantly reduced HbA1c levels for all three rs7903146 genotypes (CC: –0.82 %; CT: –0.77 %; TT: –0.57 %). A significantly smaller effect of therapy was observed with the genotype with ТТ. The rs622342 polymorphism of SLC22A1 gene was studied in effectiveness of metformin. The researches demonstrated that carriers of variant AA had an average decrease of HbA1c of 0.53 %, heterozygous – decrease of 0.32 %, and carriers of a minor variant of SS had an increase of 0.2 % in the level of HbA1c. A significant effect of CYP2C9 polymorphisms on the pharmacokinetic parameters of PSM was noted. When studying the kinetics of glibenclamide, it was found that carriage of the allele *2 significantly reduces glibenclamide metabolism: homozygous carriers had clearance 90 % lower than homozygous carriers of the wild variant. The studies confirmed the association of the allelic variants of Thr394Thr and Gly482Ser of PPARγ gene with higher efficacy of the rosiglitazone. The data obtained from the analysis of the association of the Pro12Ala polymorphism of PPARγ gene and the response to therapy is contradictory. Thus the personalized approach, based on the knowledge of polymorphism options, will allow choosing the most effective drug with transparent kinetics for each individual patient.
- 13 July 2020
- Published by FSPSI SCFHHRP in Acta Biomedica Scientifica
- Vol. 5 (3) , 13-23
Open AccessPharmacogenetic Aspects of Type 2 Diabetes Treatment
In this article, we analyze the role of different variants of the KCNJ11, TCF7L2, SLC22A1, SLC22A3, CYP2C9, CYP2C8, PPARγ genes polymorphisms in efficacy of diabetes mellitus pharmacotherapy. T allele of the KCNJ11 rs2285676 gene polymorphism and G allele of KCNJ11 rs5218 gene polymorphism are associated with the response to IDPP-4 therapy; the presence of KCNJ11 gene rs5210 polymorphism A allele is a predictor of poor response. The effect of rs7903146 polymorphism of TCF7L2 gene was evaluated on the response to treatment of patients taking linagliptin. Linagliptin significantly reduced HbA1c levels for all three rs7903146 genotypes (CC: –0.82 %; CT: –0.77 %; TT: –0.57 %). A significantly smaller effect of therapy was observed with the genotype with ТТ. The rs622342 polymorphism of SLC22A1 gene was studied in effectiveness of metformin. The researches demonstrated that carriers of variant AA had an average decrease of HbA1c of 0.53 %, heterozygous – decrease of 0.32 %, and carriers of a minor variant of SS had an increase of 0.2 % in the level of HbA1c. A significant effect of CYP2C9 polymorphisms on the pharmacokinetic parameters of PSM was noted. When studying the kinetics of glibenclamide, it was found that carriage of the allele *2 significantly reduces glibenclamide metabolism: homozygous carriers had clearance 90 % lower than homozygous carriers of the wild variant. The studies confirmed the association of the allelic variants of Thr394Thr and Gly482Ser of PPARγ gene with higher efficacy of the rosiglitazone. The data obtained from the analysis of the association of the Pro12Ala polymorphism of PPARγ gene and the response to therapy is contradictory. Thus the personalized approach, based on the knowledge of polymorphism options, will allow choosing the most effective drug with transparent kinetics for each individual patient.